Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

Thu, 28th Mar 2024 08:08

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

It is also despite unrevised numbers from the Office for National Statistics confirming the UK entered a technical recession in the fourth quarter of 2024.

"The only thing that investors need is the Federal Reserve rate cut dream to stay alive for the June meeting. And for now, that's the case. Activity on Fed funds futures gives around 64% chance for a June rate cut," said Swissquote Bank analyst Ipek Ozkardeskaya.

"But note that, this probability was around 75% last week and it's coming lower as many investors think that the Fed won't be able to cut the rates with robust growth and bumpy inflation. And indeed, the US latest GDP update is due today and is expected to confirm an above 3% growth for the US economy in the last quarter of last year, down from almost 5% printed a quarter earlier. These levels don’t call for an imminent Fed cut."

In early corporate news, JD Sports said it outperformed the sportswear market in its full-year, with like-for-like sales growing.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.3% at 7,955.13

----------

Hang Seng: up 1.1% at 16,564.84

Nikkei 225: closed down 1.5% at 40,168.07

S&P/ASX 200: closed up 1.0% at 7,896.90

----------

DJIA: closed up 477.75 points, 1.2%, at 39,760.08

S&P 500: closed up 44.91 points, 0.9%, at 5,248.49

Nasdaq Composite: closed up 83.82 points, 0.5%, to 16,399.52

----------

EUR: down at USD1.0802 (USD1.0823)

GBP: down at USD1.2615 (USD1.2630)

USD: up at JPY151.38 (JPY151.35)

Gold: up at USD2,193.16 per ounce (USD2,190.33)

(Brent): up at USD85.66 a barrel (USD85.41)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

08:55 GMT Germany unemployment

09:00 GMT eurozone money supply

12:30 GMT US GDP

12:30 GMT US initial jobless claims

14:00 GMT US pending home sales

14:00 GMT US Michigan consumer sentiment index

15:00 GMT US Kansas City Fed manufacturing activity

----------

The UK slipped into a technical recession in the fourth quarter of 2023, numbers from the Office for National Statistics confirmed on Thursday. UK gross domestic product slumped 0.3% in the three months to December from a quarter earlier, unchanged from initial ONS numbers provided in February. The UK economy had declined 0.1% quarter-on-quarter in the third-quarter of 2023. It means the UK has entered a technical recession at the end of last year, which is generally defined as two successive quarterly falls in gross domestic product. In output terms for the fourth quarter, the ONS said there were falls in all three main sectors: services down 0.1%, production down 1.1% and construction output down 0.9%. Meanwhile, in expenditure terms, there was a fall in the volume of net trade, household consumption and gross capital formation, according to the ONS, partially offset by an increase in government consumption.

----------

The US Federal Reserve should either scale back or delay its interest rate cuts in response to "disappointing" inflation data, a senior Federal Reserve official said. "In my view, it is appropriate to reduce the overall number of rate cuts or push them further into the future in response to the recent data," Fed Governor Christopher Waller told a conference in New York. "Shorter-term inflation measures are now telling me that progress [in reducing inflation] has slowed and may have stalled. But we will need more data to know that," he added. "I see economic output and the labour market showing continued strength, while progress in reducing inflation has slowed," Waller said. "Because of these signs, I see no rush in taking the step of beginning to ease monetary policy," he continued.

----------

BROKER RATING CHANGES

----------

Jefferies cuts Diploma to 'hold' (buy) - price target 3,950 (3,750) pence

----------

Exane BNP cuts Aviva to 'underperform' ('neutral') - target 420 (445) pence

----------

Exane BNP cuts Legal & General to 'neutral' ('outperform') - target 270 (280) pence

----------

COMPANIES - FTSE 100

----------

Retailer JD Sports said it outperformed the sportswear market in the 53 weeks that ended February 3. It said like-for-like sales rose 4.2% on-year and up 8.4% organically on a constant currency basis, while total sales grew 3.6% to around GBP10.5 billion. It expects pretax profit to be in line with its guided range of GBP915 million to GBP935 million, down from GBP991.4 million a year earlier. "We made good strategic progress, opening 215 new JD stores, and focusing our effort on developing JD and enhancing EPS through taking full control of ISRG and MIG," said Chief Executive Officer Regis Schultz. It outlined its initial financial 2025 profit forecast of GBP900 million to GBP980 million, while saying trading in the new financial year-to-date is in line with its expectations after seven weeks. Schultz continued: "Looking ahead, the current trading environment remains challenging due to less product innovation and elevated promotional activity, especially online. We anticipate trading conditions will improve as we move through the year, helped by a busy sporting summer and softer comparatives with last year."

----------

The UK Competition & Markets Authority decided not to refer the planned acquisition by FTSE 100-listed insurer Aviva of AIG's life-insurance and retirement-services division AIG Life to a phase 2 investigation. The UK competition watchdog said this decision was based on the information currently available and that a further announcement on the decision will be made "as soon as is reasonably practicable". In February, the CMA said it was investigating the deal, saying it could reduce competition in the UK services sector.

----------

COMPANIES - FTSE 250

----------

Automated test and assurance solutions provider Spirent said it agreed to a GBP1.16 billion takeover from Keysight Technologies. Spirent said the offer was superior to Viavi's existing GBP1.01 billion bid. The latest offer rates Spirent at 201.5 pence per share, 199.0p in cash and 2.5p in a special dividend. Spirent Chair Bill Thomas commented: "The board of Spirent is pleased to recommend Keysight's cash offer for Spirent, which is an increase of 15% to the Viavi proposal." Chief Executive Officer Eric Updyke added: "Keysight's offer for Spirent will provide further opportunities for our employees and strengthens our customer offering, given Keysight's technology expertise, capabilities and robust global platform with its breadth and depth of industry-leading solutions."

----------

OTHER COMPANIES

----------

Cancer and immunological diseases treatments developer Hutchmed said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration. If accepted, the new label indication for savolitinib will be expanded to include treatment-naive patients, those that have not received any treatment, in China. Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. "More than a third of the world's lung cancer patients are in China," Hutchmed noted.

----------

Troubled utility Thames Water has said its shareholders will not be injecting the first GBP500 million of funding that was agreed last summer into the group as industry regulations make its business plan "uninvestible". Thames Water – the UK's biggest water supplier with 15 million households across London and the South East – said the funding plan drawn up last July was subject to conditions, including a business plan that is supported by "appropriate regulatory arrangements". It said the regulations being imposed by industry watchdog Ofwat "make the PR24 plan "uninvestible", and as a result the shareholder support letter from last July "has not been satisfied".

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
2 Apr 2014 09:09

UK BROKER RATINGS: Canaccord Raises Weir Group Target To 3,000p

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
JPMORGAN RESUMES STANDARD LIFE WITH 'OVERWEIGHT'
----------
CANACCORD CUTS ABERDEEN ASSET MANAGEMENT TARGET TO 460

Read more
2 Apr 2014 08:48

Wednesday broker round-up UPDATE

Aberdeen Asset Management: Canaccord Genuity reduces target price from 540p to 460p, while its buy recommendation is kept. Anglo American: JP Morgan ups target price from 1260p to 1300p, while leaving its underweight rating unchanged. Aviva: JP Morgan raises target price from 528p to 570p maintain

Read more
14 Mar 2014 10:08

UK BROKER RATINGS: SocGen Raises IMI To Buy From Hold

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
JEFFERIES CUTS G4S PRICE TARGET TO 280 (290) PENCE - 'BUY'
----------
GOLDMAN RAISES PRUDENTIAL PRICE TARGET TO 1600

Read more
14 Mar 2014 09:07

Friday broker round-up UPDATE

Barclays: Nomura reduces target price from 305p to 285p staying with its buy recommendation. Investec lowers target price from 305p to 295p and keeps its buy recommendation. Ferrexpo: Westhouse Securities increases target price from 190p to 220p and reiterates a buy recommendation. F&C Asset Manag

Read more
14 Mar 2014 08:23

UK MORNING BRIEFING: Shares Open Lower; BP Gets US Bid Approval

LONDON (Alliance News) - Shares have opened lower Friday on geopolitical worries ahead of the weekend, despite some good news for UK companies.

The US government on Thursday decided to lift the ban on BP from federal government contracts imposed after the Deepwater

Read more
19 Feb 2014 10:07

UK BROKER RATINGS: Four Brokers Raise BHP Billiton Price Target

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
GOLDMAN RAISES HAMMERSON PRICE TARGET TO 590 (569) PENCE - 'NEUTRAL'
----------
SOCGEN RAISES BHP BILLITON PRICE T

Read more
18 Feb 2014 11:18

Hutchison China MediTech Full-Year Profit Falls, Revenue Doubles

LONDON (Alliance News) - Hutchison China MediTech Ltd on Tuesday reported a fall in profits for the 2013 financial year, but it more than doubled its revenues during the period, driven by a strong performance from its China Healthcare division. For the financial year ended December 31 2013,

Read more
18 Feb 2014 10:05

UK BROKER RATINGS: Four Brokers Raise Hammerson Price Target

LONDON (Alliance News) - The following UK shares received analyst recommendations Tuesday morning:
----------
FTSE 100
----------
CITIGROUP CUTS ROLLS-ROYCE TO 'NEUTRAL' ('BUY')
----------
BERENBERG CUTS TATE & LYLE PRICE TARGET TO 775 (900)

Read more
16 Oct 2013 16:19

Hutchison China MediPharma director takes stake in company

Edith Shih, a Non-Executive Director and Company Secretary of Hutchison China MediPharma, acquired 20,000 shares in the firm, which is the holding company of a healthcare group based primarily in China and focused on researching, developing, manufacturing and selling pharmaceuticals and health orien

Read more
16 Oct 2013 13:23

DIRECTOR DEALINGS: Hutchison China MediTech Limited Non-Exec Buys 20K Shares

Read more
9 Oct 2013 10:58

Hutchison signs Chinese licensing and marketing deal with Eli Lilly

A business majority owned by Hutchison China MediPharma has entered into a licensing, co-development, and commercialisation agreement in China with US pharmaceutical manufacturer Eli Lilly. The agreement relates to Fruquintinib, an oncology therapy for the potential treatment of various types of s

Read more
9 Oct 2013 07:57

Wednesday broker round-up UPDATE

Air Partner: Liberum Capital initiates with a target price of 555p and a buy recommendation. Alent: Credit Suisse moves target price from 420p to 430p and keeps an outperform rating. AZ Electronic Materials: Credit Suisse revises target price from 350p to 330p, while staying with its neutral ratin

Read more
9 Oct 2013 07:48

Hutchison China Meditech In Eli Lilly China Deal For Cancer Treatment

Read more
8 Aug 2013 15:57

Inmarsat Chairman sells 1.4m pounds-worth of shares

The Chairman of Inmarsat made 1.4m pounds this week by selling around a fifth of his stake in the satellite operator, the firm announced on Thursday. Andrew Sukawaty, who joined the firm 10 years ago, sold 200,000 shares in the company at a price of 700p each, taking advantage of the stock's 20% ri

Read more
30 Jul 2013 09:16

STOCKS NEWS EUROPE-UK small caps edge higher

The FTSE Small Cap index firms 0.1 percent, mirroring strength from the blue chips, while junior-listed AIM shares drop 0.1 percent. China-based healthcare and consumer products group Hutchison China Meditech is a good gainer on the AIM index, up 5.7 percent, after it accompanies its first

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.